Board of Directors

Mark A. Goldsmith, M.D., Ph.D., Chairman

Founding President, CEO and Director, Revolution Medicines

Previously, Partner with Third Rock Ventures in its West Coast office. Prior to this, Dr. Goldsmith served as President and Chief Executive Officer of Constellation from 2009 to 2012. He previously held senior executive positions in the biotechnology industry, including Senior Executive-in-Residence at Prospect Venture Partners, CEO of Cogentus Pharmaceuticals and Senior Vice President of Genencor International. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies.


James E. Audia, Ph.D.

Executive Director of the Chicago Biomedical Consortium

Dr. Jim Audia currently serves as Executive Director of the Chicago Biomedical Consortium, a collaborative effort of Northwestern University, The University of Chicago and The University of Illinois-Chicago, focused on enhancing biomedical innovation in the greater Chicago area. He joined the CBC after a nearly seven-year tenure as Constellation Pharmaceuticals’ chief scientific officer, where he oversaw the successful evolution of the company’s R&D efforts from a strong scientific base to a robust portfolio of clinical-stage assets and pre-clinical programs. Dr. Audia had joined Constellation in January 2011 following a highly productive career in drug discovery at Eli Lilly and Company. He held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, he made seminal technical and strategic contributions to the Lilly drug pipeline. Over the course of his career, Dr. Audia’s scientific work has contributed to more than 17 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor. Dr. Audia is a named inventor on more than 100 issued U.S. patents and has published and presented extensively. He received his Ph.D. in Organic Chemistry from the University of South Carolina and did postdoctoral training at Yale University before joining Lilly. Dr. Audia currently serves as a scientific advisor for Sage Therapeutics, Ribon Therapeutics, and the Tau Consortium of the Rainwater Foundation.


Anthony Evnin, Ph.D.

Partner, Venrock

Dr. Evnin is a Partner of Venrock, a venture capital firm, where he has been a Partner since 1975. He currently serves on the boards of AVEO Pharmaceuticals, Inc., Infinity Pharmaceuticals, Inc., and Pharmos Corporation as well as a number of private companies. Dr. Evnin is a Trustee of The Rockefeller University, a Trustee of The Jackson Laboratory, a Trustee Emeritus of Princeton University, and a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center. Dr. Evnin holds a Ph.D. in Chemistry from the Massachusetts Institute of Technology and an A.B. from Princeton University.


Peter Svennilson

Managing Partner and Founder, The Column Group

Peter has 30 years of experience in corporate finance, investment banking, and venture capital. He was the founder and a partner of Three Crowns Capital, a leading backer of a new generation of US biotechnology companies. He helped found companies such as Rosetta, PTC, Tercica, and Somalogic. Over the past 12 years he has helped finance and develop biotech companies, including Tularik, Sunesis, Chemocentryx, Infinity, AVEO, Rinat, and FivePrime. He is currently a Board Director of NGM Biopharmaceuticals, Immune Design, and Gritstone and has served on the Boards of several other biotechnology companies, including Seragon Pharmaceuticals (Chairman), Aragon Pharmaceuticals (Chairman), Rosetta, Somalogic, and ChemoCentryx. Before founding Three Crowns Capital, he was the Associate Managing Director of European Investment Banking Origination at Nomura Securities in London. He is currently a trustee for the Institute for Advanced Study in Princeton, New Jersey.


Robert Tepper, M.D.

Partner, Third Rock Ventures

Dr. Tepper co-founded Third Rock Ventures in 2007 and serves as a Partner. Dr. Tepper works actively with portfolio companies to shape their scientific strategy. In this capacity Dr. Tepper worked as CSO of Constellation from April 2008 to October 2009. Prior to joining Third Rock Ventures, Dr. Tepper was President of R&D at Millennium Pharmaceuticals and co-founder of Cell Genesys/Abgenix. Dr. Tepper serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several leading health care institutions including the Partners HealthCare Center for Personalized Genetic Medicine, Tufts Medical School, and a member of the Research Advisory Council of Massachusetts General Hospital.

Constellation Pharmaceuticals, Inc.
215 First Street, Suite 200
Cambridge, MA 02142

For Media Inquiries
Katie Engleman
+1 (910) 509-3977

For General Inquires
To request additional information please use:
Phone: (617) 714-0555
Fax: (617) 577-0472